Benison

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Benison

Property Description
Active Ingredient Betamethasone Dipropionate
Form Topical Formulation (Cream or Ointment)
Pharmacological Class Glucocorticosteroid (High Potency)
General Purpose Relief of severe inflammatory and pruritic skin symptoms
Origin Synthetic Adrenocorticosteroid Derivative

Understanding Benison: Classification and Origin

Benison is a powerful prescription-only medicinal preparation whose active component is Betamethasone Dipropionate, classified by regulatory authorities as a potent topical steroid. The substance is a high-potency, synthetic adrenocorticosteroid, chemically engineered to mimic and amplify the potent anti-inflammatory effects of natural corticosteroid hormones produced by the adrenal glands. This high-potency designation is crucial as it informs the drug’s specialized role in the management of acute and severe inflammatory conditions, making it distinct from milder, over-the-counter hydrocortisone preparations.

The Role of the Single-Ingredient Topical Formulation

Benison is exclusively formulated as a single-ingredient product for topical (dermatological) application, commonly available as a cream or an ointment. This formulation ensures targeted local delivery; the active substance is compounded into a specific vehicle—such as an emollient vehicle or oily base—which aids the penetration and absorption of the drug into the affected layers of the skin. The compound's structure, specifically the presence of the dipropionate ester, assists its ability to permeate the skin and ensures effective localized therapy.

General Purpose: What Benison Is Used to Achieve

The general purpose of Benison is to provide rapid and profound relief for the acute inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The core pharmacological effects of Betamethasone Dipropionate are potent anti-inflammatory, antipruritic, and vasoconstrictive actions. This combination allows the medication to effectively counteract the cellular processes that drive severe skin distress, swiftly reducing bothersome symptoms such as swelling, redness, and persistent itching.

What side effects are possible with Benison?

Possible side effects and safety information

As a high-potency topical glucocorticosteroid, Benison (Betamethasone Dipropionate) is associated with officially documented adverse reactions classified primarily as local effects on the skin and potential systemic effects from drug absorption.

Localized Skin Reactions

Adverse events most frequently manifest as Skin and subcutaneous tissue disorders at the treatment site. Initial localized reactions, such as burning, pruritus (itching), and irritation, are officially noted to occur in less than 1% of patients. Other documented reactions include dryness, folliculitis, acneiform eruptions, hypopigmentation, and allergic contact dermatitis. More significant localized effects associated with prolonged use can involve structural changes such as skin atrophy and striae.

Systemic Absorption and Endocrine Safety

Safety concerns arising from systemic exposure are primarily classified as Endocrine disorders. Significant absorption can lead to reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is recognized as a serious adverse reaction. HPA axis suppression carries the potential for glucocorticosteroid insufficiency upon treatment discontinuation. Systemic effects can also include manifestations of Cushing’s Syndrome, hyperglycemia, and glycosuria.

Exposure-Related Safety and Special Populations

Regulatory documentation states that the risk of systemic toxicity is elevated with prolonged treatment, application to large surface areas, or the use of occlusive dressings. The official safety profile also highlights that pediatric patients (children) may demonstrate a greater susceptibility to HPA axis suppression due to their higher skin surface area-to-body weight ratio. The product is not recommended for children under 12 years of age due to this heightened systemic risk.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Benison (Betamethasone Dipropionate) defines the primary overdose risk as Systemic Absorption following excessive, widespread, or prolonged topical application. This systemic exposure is officially documented to affect the Endocrine System (HPA axis) and lead to documented clinical and laboratory manifestations.

Documented Overdose Manifestations Officially Required Actions
Systemic Absorption leading to reversible HPA axis suppression Periodic evaluation for HPA axis suppression is mandated for patients using large doses over large areas.
Manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria Medical attention is required if suppression is noted, involving gradual drug withdrawal, reduction of frequency, or substitution with a less potent steroid.
Potential for Glucocorticosteroid Insufficiency upon drug withdrawal Urgent medical help is necessary for symptoms of secondary adrenal insufficiency, which may require supplemental systemic corticosteroids.

Population-Specific Risk: Pediatric patients are documented to be at greater risk of systemic toxicity due to a higher skin surface area to body mass ratio. Manifestations include linear growth retardation and signs of intracranial hypertension.

The documented overdose profile necessitates specific monitoring, such as the Urinary Free Cortisol and ACTH Stimulation tests, to confirm HPA axis suppression. The required emergency response is focused on medically supervised dosage reduction or withdrawal, and symptomatic treatment for resulting insufficiency.

Therapeutic Uses of Benison

What Benison Treats: Main Uses and Benefits

Benison is commonly used when symptoms become more noticeable, offering symptomatic relief from the distressing manifestations of corticosteroid-responsive skin conditions. It may be part of symptomatic management during acute or resistant phases of illness. The medication is indicated for the relief of inflammatory and pruritic manifestations.

The medication is generally applied in addressing symptom clusters that become difficult to tolerate, relevant for conditions involving episodic or fluctuating manifestations like plaque psoriasis, atopic dermatitis (eczema), and contact dermatitis. It is commonly used across conditions characterized by periods of heightened symptoms where short-term symptomatic assistance is considered relevant. The use of the medication is aligned with the goal of supporting patients during difficult episodes by easing distress and discomfort. By helping to moderate these distressing manifestations, the agent provides support that helps ease the overall symptom burden.

It is relevant for both Adults and Adolescents (12 and older) experiencing these challenging symptomatic phases.


Quick Fact: Relief for Intense Pruritus and Inflammation A key aspect of its use is supporting the reduction of intense itching and visible signs of inflammation (redness and swelling) in affected skin areas.


Regulatory References

  1. DailyMed: BETAMETHASONE DIPROPIONATE cream

Eligibility and Restrictions for Use

Benison’s eligibility profile is strictly defined by regulatory documents, setting clear criteria for permitted use and mandated exclusion. The final classification of patient groups must adhere to official label standards.

Eligibility Scope Status Criteria
Allowed Use Established Adults and adolescents 13 years of age and older.
Contraindicated Absolute Patients with hypersensitivity to the drug or any component, or those with specific skin conditions including rosacea, perioral dermatitis, and untreated viral, bacterial, or fungal skin infections.
Not Recommended Age-Related Children younger than 13 years due to a documented greater risk of systemic toxicity (e.g., HPA axis suppression).

Condition-specific eligibility rules mandate restricted use in several populations. Caution is required for patients with comorbidities such as liver failure or pre-existing ophthalmic conditions like cataracts or glaucoma, where increased systemic absorption may pose an additional risk. The medicine is not for ophthalmic or internal use and should be avoided on the face, groin, or axillae. Use during pregnancy and lactation is documented as conditional, and application must be limited to the smallest area and shortest duration, with direct application to the nipple or areola area advised against for breastfeeding women.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Benison (topical Betamethasone Dipropionate) is defined by its potential for systemic absorption, which subjects the high-potency corticosteroid to the interaction patterns documented for the Glucocorticosteroid class in regulatory labeling.


Documented Interaction Patterns

Category Officially Documented Interaction Implication (Regulatory Statement)
Metabolic (PK) Co-administration of strong CYP3A4 inhibitors May decrease clearance and increase Betamethasone systemic exposure.
Co-Administration Simultaneous use of other corticosteroid-containing products Formally restricted as it increases total systemic glucocorticoid exposure.
Administration Use of occlusive dressings (e.g., bandaging) Documented to substantially increase percutaneous absorption and systemic drug levels.
Pharmacodynamic (PD) Co-use with Antidiabetic agents Systemic absorption can cause hyperglycemia, acting antagonistically to the antidiabetic effect.
Pharmacodynamic (PD) Co-use with potassium-depleting agents Additive pharmacodynamic risk of low blood potassium (hypokalemia).

Population and Contextual Considerations

Certain patient factors are officially documented to increase the risk of systemic absorption and related interactions:

  • Pediatric Patients: Are at a greater risk of systemic toxicity, including HPA axis suppression, due to a higher ratio of skin surface area to body mass.
  • Liver Function: Liver failure is a documented factor that predisposes to systemic effects due to impaired clearance of the absorbed steroid.

This structure reflects the regulatory focus on mitigating the risk of increased systemic glucocorticoid exposure across various application contexts and patient populations.

Mechanism of Action

Glucocorticoid Receptor Programming

The mechanism begins at the cellular level where the active molecule acts as a high-affinity agonist for the Glucocorticoid Receptor (GR) inside skin cells. This interaction initiates a defined genomic cascade: the activated complex suppresses genes that promote inflammation (transrepression) and simultaneously upregulates genes for anti-inflammatory proteins like Annexin A1 (transactivation). This central programming fundamentally modifies the cell's transcriptional output, thereby establishing the cascade's downstream physiological consequences.


Inhibiting the Arachidonic Acid Cascade

A key consequence of this genomic programming is the inhibition of the Arachidonic Acid Cascade. The induced Annexin A1 protein inhibits the enzyme Phospholipase A2 (PLA2), preventing the release of the precursor molecules needed to generate inflammatory mediators such as prostaglandins and leukotrienes. This upstream intervention results in diminished levels of inflammatory mediators, leading to a reduction in localized fluid accumulation and nerve-irritating signals.


Local Vascular and Cellular Modulation

The drug's action culminates in defined changes at the tissue level, affecting local blood flow and immune cell activity. By suppressing vasodilatory mediators, the mechanism causes localized vasoconstriction (narrowing of dermal capillaries), which physically reduces excessive blood flow (hyperemia) and fluid leakage (edema). Furthermore, the mechanism restricts the migration and proliferation of immune cells, resulting in altered local immune pathway dynamics.

Dosage and Administration Information

How to Use Benison: Administration Guidelines

This section outlines the usage principles for Benison (Betamethasone Dipropionate 0.05% topical formulations).


Administration Scope

Feature Guideline
Route of administration: Topical (dermatologic) application only. Not for ophthalmic, oral, or intravaginal use.
Dosing schedule: Apply a thin film to the affected skin areas once or twice daily.
Preparation requirements: For Spray formulation, the product should be shaken well before use and rubbed in gently.
Age-group administration rules: Indicated for patients 13 years of age and older. Use in children 12 years of age and younger is not recommended.

Use-Context Constraints

Constraint Guideline
Duration Limits: Continuous therapy should be limited to two consecutive weeks for Cream/Ointment forms. Therapy must be discontinued when control is achieved.
Quantity Limits: The maximum quantity is limited to 50 grams per week.
Site Restrictions: Avoid use on the face, groin, or armpits (axillae), and avoid contact with the eyes.
Application Conditions: Do not use with occlusive dressings (e.g., bandages or wraps) unless specifically advised by a healthcare provider.

Connection to the Overall Use Protocol

The instructions structure the use of Benison as a short-term, high-potency intervention delivered through the topical route directly to the skin. These guidelines establish specific age, quantity, and duration limits (e.g., two consecutive weeks and 50 grams per week maximum) that define a standardized and localized approach to its administration. This framework ensures the medicine is used strictly as outlined in the prescribing information.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Benison

Research Evidence for Plaque Psoriasis

Research exploring the effects of Benison on the acute inflammatory and pruritic manifestations of plaque psoriasis primarily involves short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These studies were designed to compare the effects of the active medicine against a non-active base (vehicle) and were applied in studies examining patient-reported experiences related to physical discomfort. Researchers monitored specific physical outcomes linked to inflammatory or irritative states, such as the degree of redness, scaling, and thickness of affected skin areas.

Research Evidence for Atopic Dermatitis (Eczema)

For atopic dermatitis, Benison was evaluated in trials often categorized as vehicle-controlled. These studies were relevant in trials assessing short-term or episodic symptom patterns associated with this condition characterized by fluctuating or episodic manifestations. Research examined outcomes linked to inflammatory or irritative states, such as the physical signs of the condition and the degree of pruritus (itching). Findings describe patterns observed in the studies, helping to contextualize how patients reported their experience during the short trial duration.

Duration of Studies and Long-Term Follow-up

The research examining Benison was studied for its short-term effects. The vast majority of the pivotal clinical trials used for regulatory review are designed around a short follow-up duration, typically ranging from 2 to 4 weeks. These studies help show what has been observed so far in patients during the initial treatment phase, which is relevant in trials assessing short-term or episodic symptom patterns. Once the period of increased symptom activity is over, the long-term effects are not fully established through single-agent trials.

Research Gaps and Remaining Uncertainty

A major limitation is that the follow-up durations were limited in many primary efficacy studies, meaning there is limited information for long-term outcomes concerning symptom patterns or the durability of observed changes. The evidence base generally was evaluated in patient populations starting from Adolescents and including Adults. However, data for certain groups, such as children under the age of 12, are very limited or unavailable in the primary evidence base. The results apply only to the populations studied and do not provide robust insight into other specific populations.

Key Studies & References DailyMed: Labeling Information for BETAMETHASONE DIPROPIONATE cream

Frequently Asked Questions (FAQ)

Common questions about Benison (FAQ)

Q: What is the general difference between Benison and other similar medicines?

A: Benison’s active ingredient is classified by regulatory authorities as a high-potency topical corticosteroid. This classification places it among specialized medications used for severe skin conditions. This designation is used to clarify its specialized role compared to lower-potency preparations, such as non-prescription hydrocortisone.

Q: Can Benison cause issues with my liver or kidneys?

A: Official product information notes that, once absorbed, the drug is primarily processed by the liver and removed by the kidneys. Liver failure is documented as a factor that may increase the potential for the medicine to be absorbed systemically. The presence of these existing conditions may be a factor requiring careful consideration by a healthcare provider.

Q: Does Benison have any warning labels I should know about?

A: The official labeling includes a WARNINGS AND PRECAUTIONS section describing potential systemic effects. It specifically highlights the risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is an endocrine effect that can occur due to the drug being absorbed through the skin.

Q: Is it common to feel tired after starting Benison?

A: Fatigue or tiredness is not listed among the common local skin reactions. However, official safety information documents that severe systemic absorption can lead to endocrine disorders like Cushing's syndrome, which may include symptoms such as extreme tiredness.

Q: What happens if I miss a dose of Benison?

A: Patient information guides generally advise that if a dose is missed, it should be applied as soon as it is remembered. However, if it is nearly time for the next scheduled application, some patient information guides advise skipping the forgotten dose to return to the regular schedule.

Q: Can Benison be taken with over-the-counter pain relievers?

A: Official patient advice emphasizes that individuals should inform their healthcare provider about all medicines they use, including any over-the-counter pain relievers. This practice allows a healthcare provider to assess for any potential interactions or increased risk of systemic exposure from using multiple products.

Q: What foods or supplements might interact with Benison?

A: Official guidance on interactions focuses on drug-drug risks. However, patient information advises individuals to tell their healthcare provider about all medicines, vitamins, and any herbal supplements they are taking, which may be an area of consideration for a healthcare provider when discussing the risk of potential interactions.

Q: How long does Benison stay in the body?

A: According to regulatory pharmacokinetics data, once the active ingredient is absorbed into the bloodstream, its systemic half-life is documented as approximately 36 to 54 hours. The body processes and eliminates the drug primarily via the liver and kidneys.

Q: Is Benison a controlled substance?

A: Benison is officially classified as a prescription-only medicine. Regulatory documents indicate that the drug is not listed as a controlled substance under the Drug Enforcement Administration (DEA) Schedule.

Q: Why do some people say Benison causes headaches?

A: Headache is listed as a possible side effect in official safety information. Regulatory reports in pediatric patients have also described headache as a manifestation of a rare, systemic reaction called intracranial hypertension.

Q: Does Benison affect blood pressure?

A: Studies and safety information indicate that systemic absorption of the drug can potentially lead to endocrine effects. Hypertension (high blood pressure) is listed as a possible systemic adverse reaction in some safety documentation.

Q: Is Benison available as a generic medicine?

A: Yes, the active ingredient in Benison is available in generic formulations. Official documents confirm that the medicine is marketed under an Abbreviated New Drug Application (ANDA), indicating the availability of authorized generic equivalents.

Q: Can Benison cause problems with sleep?

A: Official safety information lists difficulty falling asleep (insomnia) as a possible adverse reaction. This is generally considered a systemic effect related to the drug's corticosteroid action.

Q: Does taking Benison affect mood?

A: Official safety data indicates that taking topical corticosteroids may affect mood in rare cases. Possible systemic side effects listed include mood swings, emotional instability, depression, and nervousness.

Q: Is it true that Benison can cause weight changes?

A: While weight gain is not listed as a common side effect, systemic absorption has been known to lead to manifestations of Cushing's syndrome. This condition is medically associated with changes in weight and has been specifically reported in pediatric patients.

Q: Does Benison require special monitoring like blood tests?

A: Because of the potential for systemic absorption, the medicine may require special monitoring. Evaluation for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression is done using specific laboratory tests, such as the ACTH stimulation test.

Q: What is the risk of developing a dependency on Benison?

A: Long-term or prolonged use carries the risk of adrenal suppression and a documented skin reaction upon discontinuation. This reaction must be managed under the care of a healthcare professional, but the official labeling typically avoids the specific term 'dependency.'

Q: Does Benison interact with commonly prescribed heart medications?

A: The official interaction profile lists drug classes that interact with the medicine if systemic absorption occurs. These classes include potassium-depleting agents and CYP3A4 inhibitors, which may include certain commonly prescribed heart medications or diuretics.

Q: Can I take Benison if I have a history of a certain medical condition?

A: The product requires careful consideration by a healthcare professional for patients with a history of specific medical conditions, as its use is subject to caution or contraindication. These conditions include hypersensitivity to the drug's components, certain skin infections, liver failure, and pre-existing ophthalmic conditions like glaucoma or cataracts.

Q: Is Benison available in different strengths?

A: The active ingredient in Benison is available in different topical formulations, such as cream and ointment. The regulatory documents confirm that it is available in various strengths for different clinical contexts.

Q: What is the expected timeline for seeing the full effects of Benison?

A: The pivotal clinical trials evaluating the drug’s effects were typically short-term, with follow-up periods of 2 to 4 weeks. Regulatory guidance recommends that therapy be discontinued promptly once the desired symptom control is achieved, indicating it is intended for a brief, high-impact treatment course.

Q: Does Benison have a risk of causing serious allergic reactions?

A: Safety documentation indicates that local reactions, such as allergic contact dermatitis, are possible. Furthermore, serious allergic reactions (anaphylaxis) have been reported in post-marketing experience, though these events are considered rare.

Q: What should I do if a specific side effect gets worse?

A: Official patient information advises reporting any local adverse reactions, or signs of worsening side effects, to a healthcare provider. If a serious systemic reaction like HPA axis suppression is confirmed by testing, the official protocol indicates the treatment should be managed for gradual withdrawal under medical supervision.

Q: Is Benison associated with hair loss?

A: Hair loss (thinning of the hair) is listed in official safety information as a less common, local side effect. Conversely, increased hair growth, known as hypertrichosis, at the application site is also noted as a possible reaction.

Q: Can Benison affect fertility?

A: Official documents state that long-term studies to evaluate the effect on human fertility have not been conducted. Based on the available data, there is no definitive evidence to suggest that the medicine affects fertility in men or women.

Q: Are there known interactions between Benison and herbal supplements?

A: Patient information advises that individuals should disclose all substances being taken to their healthcare provider. This includes prescription medicines, over-the-counter products, vitamins, and herbal supplements to fully assess the risk of potential interactions.

Q: What is the primary way the body processes and gets rid of Benison?

A: The primary process for eliminating the drug is through metabolism in the body. Once absorbed through the skin, the active component is metabolized primarily in the liver and is subsequently excreted by the kidneys.

Q: What should I do if I think Benison is not working for me?

A: Official regulatory labeling states that if a favorable response is not observed promptly, the drug should be discontinued. Cessation of use should be managed under the direction of a healthcare provider, who would then determine the appropriate next steps for managing the underlying condition.

How should Benison be stored and disposed of?

The storage and disposal instructions for Benison (Betamethasone Dipropionate Cream) are strictly defined in the official regulatory labeling to ensure product stability and safety.

Storage Requirements

Benison must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F). The product must be protected from freezing, and the container should be kept tightly closed.

It is a mandatory requirement that the medicine be kept out of the reach of children.

Disposal Instructions

Unused or expired Benison must be disposed of according to local regulations. The official guidance explicitly states that the medicine should not be flushed down a toilet or poured into any drain or wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Benison found in:

A-Z Index: